TABLE 3.

Cross-validation of imputation method for a) cervix, b) prostate, and c) colorectal cancer

a. Cervix Cancer
		Imputed value
Real value		Foreign-born	U.S.-born	Total
Foreign-born		986(70.13%)	50(3.56%)	1,026(73.02%)
U.S.-born		46(3.27%)	324(23.04%)	370(26.32%)
Total		1,032(73.40%)	374(26.60%)	1,406 (100.0%)
% misclassified		6.83%
Kappa		0.8245
Sensitivity		95.17%
Specificity		86.81%
b. Prostate Cancer
		Imputed value
Real value		Foreign-born	U.S.-born	Total
Foreign-born		2,839(53.79%)	183(3.47%)	3,022(57.22%)
U.S.-born		234(4.473%)	2,025(38.35%)	2,259(42.78%)
Total		3,073(58.19%)	2,208(41.81%)	5,281 (100.0%)
% misclassified		7.90%
Kappa		0.8382
Sensitivity		93.94%
Specificity		89.64%
c. Colorectal Cancer
		Imputed value
Real value		Foreign-born	U.S.-born	Total
Foreign-born		1,818(45.67%)	186(4.67%)	2,004(50.34%)
U.S.-born		199(5.00%)	1,778(44.66%)	1,977(49.66%)
Total		2,017(50.67%)	1,964(49.33%)	4382 (100.0%)
% misclassified		9.67%
Kappa		0.8066
Sensitivity		90.72%
Specificity		89.93%